Mepolizumab for Chronic Rhinosinusitis

(ISS-RESMEPO Trial)

Recruiting at 1 trial location

Overseen By Leandra Mfuna Endam, Msc

Age: 18+

Sex: Any

Trial Phase: Phase 4

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Must be taking: Intranasal corticosteroids

Must not be taking: Systemic corticosteroids, Immunosuppressives

Disqualifiers: Cystic fibrosis, HIV, Acute sinusitis, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 12

Duration: 48 weeks

36 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to understand how mepolizumab, a medication approved for conditions like asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), provides long-lasting relief for some patients. Researchers seek to identify why some people experience prolonged benefits from the treatment, even after stopping it. The trial includes patients with CRSwNP who have had nasal polyps in both nostrils and have undergone surgery for nasal polyps in the past 10 years. Participants should also have severe symptoms that might require surgery, such as nasal blockages or a loss of smell.

As a Phase 4 trial, this research focuses on understanding how this FDA-approved and effective treatment can benefit more patients.

Will I have to stop taking my current medications?

The trial requires that you stop using systemic corticosteroids (oral steroids) at least 4 weeks before screening and avoid them during the study. You must also stop any biological or immunosuppressive treatments (except Xolair) before the trial, and you cannot start or change allergen immunotherapy doses within 3 months before the trial.

What is the safety track record for this treatment?

Research has shown that mepolizumab is generally safe for people with chronic rhinosinusitis with nasal polyps (CRSwNP). In clinical studies, most patients experienced only mild side effects, such as headaches, back pain, and injection site reactions, which are common with many injectable treatments.

Mepolizumab targets a protein called IL-5, involved in inflammation. The FDA has already approved this treatment for CRSwNP, indicating it has passed thorough safety checks. Studies have also demonstrated that mepolizumab can lead to lasting symptom improvements, even after stopping the treatment.

While serious side effects are rare, they can occur, including allergic reactions. Discussing with a healthcare provider can help determine if this treatment is suitable based on personal health history. ^{1 2 3 4 5}

Why are researchers enthusiastic about this study treatment?

Unlike the standard treatments for chronic rhinosinusitis, which often include nasal corticosteroids and antibiotics, Mepolizumab targets a specific pathway in the immune system. Mepolizumab is a monoclonal antibody that works by blocking interleukin-5 (IL-5), a protein that plays a key role in the inflammation associated with this condition. This targeted approach could potentially offer more effective relief with fewer side effects. Researchers are excited because Mepolizumab's unique mechanism of action could provide a new option for patients who don't respond well to existing therapies.

What is the effectiveness track record for mepolizumab in treating chronic rhinosinusitis with nasal polyps?

Research has shown that mepolizumab effectively treats chronic rhinosinusitis with nasal polyps (CRSwNP). In real-world studies, patients using mepolizumab experienced significant improvements in symptoms and quality of life. Specifically, reports indicated smaller polyps and fewer required surgeries. Patients also felt less burdened by their treatment, as reflected in improved scores on the SNOT-22 questionnaire, which measures the impact of sinus symptoms. Mepolizumab is approved for CRSwNP and has demonstrated lasting benefits, even after treatment cessation. ^{3 6 7 8 9}

Who Is on the Research Team?

Martin Yvon Desrosiers, MD

Principal Investigator

Centre hospitalier de l'Université de Montréal (CHUM)

Are You a Good Fit for This Trial?

This trial is for people with severe nasal polyps and chronic rhinosinusitis who've had at least one related surgery in the last 10 years. They must have ongoing symptoms despite using nasal steroid treatments for over 4 weeks. Excluded are those with recent nose surgeries, certain allergies, HIV, or reactions to similar drugs; also excluded are pregnant women not using effective contraception.

Inclusion Criteria

You have a condition affecting both sides of your nasal passages, diagnosed by a doctor using an endoscope or historical CT scan.

I have had symptoms like nasal blockage, discharge, facial pain, or loss of smell for over 12 weeks.

I have had nasal polyp surgery in the last 10 years.

Exclusion Criteria

I have been diagnosed with a specific lung condition like Churg Strauss syndrome.

I have not had nose or sinus surgery in the last 6 months.

I am currently experiencing a persistent stuffy nose due to long-term nasal spray use.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive mepolizumab 100mg SC once every 4 weeks for 48 weeks

48 weeks

12 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 months

Long-term follow-up

Persistent clinical response to mepolizumab is assessed after cessation of treatment

18 months

What Are the Treatments Tested in This Trial?

Interventions

• Mepolizumab

Trial Overview

The study tests Mepolizumab's long-term effects on patients with chronic rhinosinusitis and nasal polyps. It explores how this drug might lead to lasting improvements even after treatment ends by affecting various biological processes beyond just reducing inflammation caused by eosinophils.

How Is the Trial Designed?

Group I: Mepolizumab 100mg injection Experimental Treatment 1 Intervention

Mepolizumab 100mg SC once every 4 weeks for 48 weeks (twelve injections)

Who Is Running the Clinical Trial?

Centre hospitalier de l'Université de Montréal (CHUM)

Lead Sponsor

Trials

389

Recruited

143,000+

Published Research Related to This Trial

In the phase III SYNAPSE study involving 407 patients, mepolizumab significantly reduced nasal polyp size and nasal obstruction in chronic rhinosinusitis with nasal polyps, showing efficacy across various subgroups including those with asthma and aspirin-exacerbated respiratory disease (AERD).

Patients receiving mepolizumab demonstrated a higher rate of improvement in nasal polyp scores and nasal obstruction compared to those on placebo, indicating that mepolizumab is effective regardless of baseline blood eosinophil counts.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count. Bachert, C., Sousa, AR., Han, JK., et al.[2022]

In a study of 351 patients with severe eosinophilic asthma, initiating treatment with mepolizumab led to a significant reduction in the use of high-dose inhaled corticosteroids (ICS) over a 12-month period, with 49% of patients reducing or discontinuing ICS.

Patients who discontinued ICS after starting mepolizumab experienced lower rates of chronic oral corticosteroid (OCS) use, fewer exacerbations, and reduced reliance on short-acting β2-agonists, indicating improved clinical outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumab. Corren, J., Silver, J., Molfino, NA., et al.[2022]

In the 52-week Phase III SYNAPSE study, mepolizumab significantly reduced nasal polyp size and improved symptoms in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), showing sustained benefits even 24 weeks after treatment discontinuation.

Among 134 patients followed up, those who received mepolizumab had better outcomes, such as lower nasal polyp scores and reduced need for sinus surgery, compared to placebo, indicating that the treatment's effects can last beyond the treatment period.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up. Desrosiers, M., Diamant, Z., Castelnuovo, P., et al.[2023]

In a comprehensive eight-year follow-up study of pediatric bone cancer patients receiving aprepitant, adverse events such as anorexia, febrile neutropenia, and headache occurred at rates exceeding 43.8 per 100 patients, which is higher than previously reported.

The findings highlight a significant concern regarding the safety of aprepitant in this population, particularly the increased risk of febrile neutropenia, suggesting a need for further safety investigations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Adverse events associated with aprepitant pediatric bone cancer patients. Okumura, LM., da Silva Ries, SA., Meneses, CF., et al.[2019]

In a study involving 200 children undergoing chemotherapy, palonosetron (PG) demonstrated comparable efficacy to ondansetron (OG) in preventing nausea and vomiting, with complete response rates of 88% for PG versus 84% for OG in the acute phase.

Palonosetron was found to be more cost-effective than ondansetron, making it a suitable option for healthcare facilities in resource-limited settings, while maintaining similar safety profiles.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial. Chaudhary, NK., John, RR., Boddu, D., et al.[2019]

A 62-year-old female patient with chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma experienced complete recovery of her sense of smell after 4 months of treatment with mepolizumab, a medication typically used for severe asthma.

Mepolizumab treatment led to good control of both asthma and CRSwNP symptoms, suggesting that it may effectively reduce nasal obstruction caused by polyps, thereby improving olfactory function.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Recovery of smell sense loss by mepolizumab in a patient allergic to Dermatophagoides and affected by chronic rhinosinusitis with nasal polyps. Cavaliere, C., Incorvaia, C., Frati, F., et al.[2022]

In a study involving 20 adult patients with eosinophilic chronic rhinosinusitis, treatment with mepolizumab for 24 weeks significantly reduced eosinophil counts in sinonasal tissue, indicating its efficacy in targeting IL-5 to suppress eosinophil trafficking.

Despite the reduction in eosinophils, levels of type-2 cytokines (IL-5, IL-4, IL-13, and GM-CSF) increased in the tissue, suggesting a potential local inflammatory feedback loop that may contribute to incomplete treatment responses.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mepolizumab decreases tissue eosinophils while increasing type-2 cytokines in eosinophilic chronic rhinosinusitis. Walter, S., Ho, J., Alvarado, R., et al.[2023]

In a 48-week study of 11 patients with severe eosinophilic asthma and chronic rhinosinusitis, mepolizumab significantly reduced blood eosinophil counts and improved lung function and nasal symptoms, indicating its efficacy in treating both upper and lower airway issues.

All patients who were dependent on oral corticosteroids were able to successfully withdraw from these medications, highlighting the potential of mepolizumab as a safer alternative for managing severe asthma.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Favorable clinical efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma: a 48-week pilot study. Kurosawa, M., Ogawa, E., Sutoh, E.[2020]

In a real-world study involving 950 patients with severe asthma and chronic rhinosinusitis (CRS), mepolizumab significantly reduced asthma exacerbations by 28% to 44%, with the greatest improvement seen in patients who had both CRS and sinus surgery.

After starting mepolizumab, patients experienced lower use of systemic corticosteroids and reduced healthcare costs, indicating its efficacy in managing severe asthma and CRS in clinical practice.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Real-world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: impact of comorbidity and sinus surgery. Silver, J., Deb, A., Laliberté, F., et al.[2023]

In a study of 88 patients with non-Hodgkin lymphoma receiving moderately emetogenic chemotherapy, palonosetron demonstrated increasing efficacy, with complete response rates rising from 68.2% in the first cycle to 80.5% in the second cycle, and over 90% of patients remained emesis-free without additional antiemetics.

Palonosetron showed a favorable safety profile, with only 8% of treatment-emergent adverse events related to the drug, indicating it is a safe option for managing chemotherapy-induced nausea and vomiting.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy. Choi, BS., Borsaru, GP., Ballinari, G., et al.[2021]

A systematic review of antiemetic agents for preventing chemotherapy-induced nausea and vomiting (CINV) in children found that these medications, including aprepitant and ondansetron, are generally safe with manageable adverse effects.

While the recommended antiemetics are effective, it is important to consider individual patient risk factors, particularly for rare side effects like cardiac arrhythmia, and further research is needed to assess their long-term safety in pediatric cancer patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis. Patel, P., Paw Cho Sing, E., Dupuis, LL.[2019]

In a study of 55 patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) treated with mepolizumab, significant improvements were observed in nasal symptoms and polyp scores after 6 months, particularly in patients with aspirin-exacerbated respiratory disease (AERD).

Mepolizumab treatment led to a marked reduction in blood eosinophil levels and decreased reliance on systemic corticosteroids, enhancing the overall quality of life for patients with CRSwNP, regardless of asthma status.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Real-Life Effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps. Domínguez-Sosa, MS., Cabrera-Ramírez, MS., Marrero-Ramos, MDC., et al.[2023]

Citations

1.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/40978169/

Mepolizumab for the management of chronic rhinosinusitis ...

In this first retrospective mepolizumab study for patients with CRSwNP without severe asthma, improvements in all outcomes were observed ...

2.

jacionline.org

jacionline.org/article/S0091-6749(24)02320-0/fulltext

Mepolizumab Improves Patient-Reported Outcomes and ...

In real-world patients with CRSwNP, mepolizumab substantially improved SNOT-22 scores and treatment burden.

3.

sciencedirect.com

sciencedirect.com/science/article/pii/S0196070924003831

Mepolizumab in chronic rhinosinusitis with nasal polyps

The results are promising in terms of quality of life, symptom severity, reduction in polyp size, and improvement in olfactory function. Finally, our data ...

4.

jaci-global.org

jaci-global.org/article/S2772-8293(25)00150-X/fulltext

Mepolizumab for the management of chronic rhinosinusitis ...

Mepolizumab was found to improve nasal symptoms and health-related quality of life and to reduce NP size, number of nasal surgeries, and SCS receipt in patients ...

5.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/38696895/

Effectiveness and safety profile of mepolizumab in chronic ...

Results: A total of 30 patients were treated with Mepolizumab, one patient discontinued the treatment. A statistically significant reduction in the Sino-Nasal ...

6.

sciencedirect.com

sciencedirect.com/science/article/pii/S0196070924001157

Effectiveness and safety profile of mepolizumab in chronic ...

Mepolizumab was approved for the treatment of CRSwNP in 2021, it may be useful to evaluate its safety profile in a real-world setting.

7.

nucalahcp.com

nucalahcp.com/nasal-polyps/

Learn About a CRSwNP Treatment Option

Find more information about NUCALA for chronic rhinosinusitis with nasal polyps (CRSwNP). Review safety data, clinical trials, patient profiles, and dosing.

8.

jaci-inpractice.org

jaci-inpractice.org/article/S2213-2198(24)00941-3/fulltext

Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis ...

The anti-IL-4Rα dupilumab and the anti-IL-5 mepolizumab have shown efficacy and safety data for patients with chronic rhinosinusitis with nasal ...

9.

nucala.com

nucala.com/chronic-rhinosinusitis-nasal-polyps/

Chronic Rhinosinusitis with Nasal Polyps Treatment

Important Safety Information. Do not use NUCALA if you are allergic to mepolizumab or any of the ingredients in NUCALA. NUCALA can cause serious side effects ...